1. Home
  2. SMJF vs MOLN Comparison

SMJF vs MOLN Comparison

Compare SMJF & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SMJF

SMJ International Holdings Inc. Class A Ordinary Shares

N/A

Current Price

$3.17

Market Cap

123.8M

Sector

N/A

ML Signal

N/A

Logo Molecular Partners AG

MOLN

Molecular Partners AG

HOLD

Current Price

$4.41

Market Cap

144.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SMJF
MOLN
Founded
1988
2004
Country
Singapore
Switzerland
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
123.8M
144.0M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
SMJF
MOLN
Price
$3.17
$4.41
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$8.38
AVG Volume (30 Days)
582.6K
1.9K
Earning Date
05-08-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$374.07
P/E Ratio
$68.08
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.82
$3.36
52 Week High
$5.70
$5.36

Technical Indicators

Market Signals
Indicator
SMJF
MOLN
Relative Strength Index (RSI) 43.93 49.35
Support Level $2.19 $4.04
Resistance Level $3.74 $4.50
Average True Range (ATR) 0.21 0.16
MACD 0.01 0.03
Stochastic Oscillator 6.15 66.78

Price Performance

Historical Comparison
SMJF
MOLN

About SMJF SMJ International Holdings Inc. Class A Ordinary Shares

SMJ International Holdings Inc specializes in the sale and distribution of a wide range of flooring products such as carpet tiles, broadloom carpets and vinyl tiles. The company operates under the proprietary brand 'SMJ'.The company also supplies environmentally friendly flooring products, promoting sustainable building practices in Asia. It has presence in several countries including Malaysia, Indonesia, Philippines, Hong Kong, PRC, Taiwan, Korea, Thailand, Vietnam, Brunei, and India. It generates revenue mainly through the sale and distribution of its flooring products prominently in Singapore.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.

Share on Social Networks: